Trial of retinol and isotretinoin in skin cancer prevention: A randomized, double-blind, controlled trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 11, 1997, Pages 957-961

  Levine, Norman ^a,c   Moon, Thomas E ^b,c,d   Cartmel, Brenda ^c,e   Bangert, Jerry L ^a,c   Rodney, Steven ^c   Dong, Qiong ^b   Peng, Yei Mei ^c   Alberts, David S ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d LIGAND PHARMACEUTICALS INC   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RETINOL;

ADULT; ARTICLE; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; TUMOR PROMOTION;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; VITAMIN A;

EID: 0030840112     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Moon, T. E., Levine, N., Cartmel, B., Bangert, J. L., Rodney, S., Dong, Q., Peng, Y-M., and Alberts, D. for the Southwest Skin Cancer Prevention Study Group. Effect of retinol to prevent squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidemiol. Biomark. Prev., 6: 949-956, 1997.
2. Moon, T. E., Levine, N., Cartmel, B., Bangert, J., Rodney, S., Schreiber, M., Peng, Y-M., Ritenbaugh, C., Meyskens, F., Alberts, D., and the Southwest Skin Cancer Prevention Study Group. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. Cancer Epidemiol. Biomark. Prev., 4: 661-669, 1995.
3. Halperin, M., Rogot, E., Gurian, J., and Ederer, F. Sample sizes for medical trials with special reference to long-term therapy. J. Chronic Dis., 21: 13-24, 1968.
4. Lachin, J. M. Introduction to sample size determinations and power analyses for clinical trials. Controlled Clin. Trials, 2: 73-113, 1981.
5. Peto, R., Pike, M. C., and Armitage, P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.
6. SAS Institute I. SUGI Supplemental Library User's Guide. Cary, NC: SAS Institute, 1986.
7. Moriarity, M., Dunn, J., Darragh, A., Lambe, R., and Brick, I. Etretinate in treatment of actinic keratoses. Lancet, i: 364-365, 1982.
8. Tangrea, J., Edwards, B. K., Taylor, P. R., Hartman, A. M., Peck, G. L., Salasche, S. J., Menon, P. A., Benson, P. M., Mellette, J. R., and Guill, M. A. Long term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J. Natl. Cancer Inst., 84: 328-332, 1992.
9. Greenberg, E. R., Baron, J. A., Stukel, T. A., Stevens, M. M., Mandel, J. S., Spencer, S. K., Elias, P. M., Lowe, N., Nierenberg, D. W., and Bayrd, G. A clinical trial of β carotene to prevent basal-cell and squamous-cell cancers of the skin. N. Engl. J. Med., 323: 789-795, 1990.
10. Kraemer, K. H., DiGiovana, J. J., Moshell, A. N., Tarone, R. E., and Peck, G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N. Engl. J. Med., 318: 1633-1637, 1988.
11. Moshell, A. N. Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin. Cutis, 43: 485-490, 1989.
12. Kelly, J. W., Sabto, J., Gurr, F. W., Brace, F. Retinoids to prevent skin cancer in organ transplant recipients. Lancet, 338: 407, 1991.
13. Bavick, J. N., Tieben, L. M., Van der Woude, F. J., Tegzess, A. M., Hermans, J., ter Schegget, J., and Vermeer, B. J. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J. Clin. Oncol., 13: 1933-1938, 1995.
14. Tangrea, J. A., Adrianza, E., Helsel, W. E., Taylor, P. R., Hartman, A. M., Peck, G. L., and Edwards, B. K. for the Isotretinoin-Basal Cell Carcinoma Study Group. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. Cancer Epidemiol. Biomark. Prev., 2: 375-380, 1993.